carecentrix

Provider Newsflash 2020

FDA RECALL

Purpose of this communication:

We are writing to inform you that effective immediately, the FDA has issued a voluntary nationwide recall to the consumer level of one lot of Daptomycin for Injection, 500 mg/vial due to the presence of particulate matter found in one single-dose vial manufactured by Mylan Laboratories Limited's Specialty Formulation Facility with Lot number 7605112 exp October 2021

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-initiates-voluntary-nationwide-recall-one-lot-daptomycin-injection-due-presence-particulate?utm_campaign=Mylan%20Initiates%20Recall%20of%20One%20Lot%20of%20Daptomycin%20for%20Injection%2C%20Due%20to%20The%20Presence%20of%20Particulate&utm_medium=email&utm_source=Eloqua

- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by:
    - Faxing information– To: 919-792-6718 Attn: Quality Department

Thank you for your prompt attention and cooperation in this matter.